Indivior Pharmaceuticals, Inc.

NasdaqGS:INDV Stock Report

Market Cap: US$5.0b

Indivior Pharmaceuticals Future Growth

Future criteria checks 1/6

Indivior Pharmaceuticals is forecast to grow earnings and revenue by 13.8% and 2.7% per annum respectively while EPS is expected to grow by 12.3% per annum.

Key information

13.8%

Earnings growth rate

12.33%

EPS growth rate

Pharmaceuticals earnings growth14.2%
Revenue growth rate2.7%
Future return on equityn/a
Analyst coverage

Good

Last updated06 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Aug 05

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Summary Indivior's turnaround is driven by SUBLOCADE's strong growth, improved cash flow, and a three-phase recovery plan that the market undervalues. Q2 2025 results beat expectations, with SUBLOCADE delivering 9% YoY growth and management raising full-year revenue and EBITDA guidance. Key risks include heavy reliance on SUBLOCADE, legacy product erosion, and execution risk as the company transitions and optimizes operations. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Indivior: Trying To Break Addiction

Summary Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery. An analysis around INDV stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 13

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Summary Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x. With new competition from Brixadi, Sublocade maintains 80% market share across new patients. With LAI's low-7% penetration in BMAT, having both options on the market raises awareness for both drugs. The BMAT (Buprenorphine-Medically-Assisted-Treatment) market is expected to grow at a 9.9% CAGR over the next 8 years in the US. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Indivior: Management Takes Advantage Of Sell-Off As Board Approves Another $100m Buyback

Summary Indivior shares sold off on July 9th due to unexpected negative news from management, including the discontinuation of the schizophrenia drug Perseris and lower Sublocade guidance. Below, I argue why the market overreacted to Sublocade's lower FY24 guidance and why I expect Sublocade to continue growing. Current valuation indicates a FY24 EV/EBITDA multiple of sub 5x, offering an attractive entry point if Sublocade sales prove to be robust in the long term. Confidence in Sublocade was signalled by the board's approval of an "accelerated" $100 million repurchase program, which represents 6% of outstanding shares at the current share price of $12.5. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:INDV - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20281,3745175195554
12/31/20271,2874554763816
12/31/20261,2584143863055
3/31/20261,290252-193-111N/A
12/31/20251,239210-94-27N/A
9/30/20251,181128117177N/A
6/30/20251,173108171218N/A
3/31/20251,170-7115148N/A
12/31/20241,1887536N/A
9/30/20241,182-91-245-213N/A
6/30/20241,147-248-247-194N/A
3/31/20241,124-112-351-301N/A
12/31/20231,093-126-353-300N/A
9/30/20231,042-235-89-52N/A
6/30/20231,002-59-22-11N/A
3/31/2023947-502335N/A
12/31/2022901-44-9-4N/A
9/30/2022882166176181N/A
6/30/2022838152160145N/A
3/31/2022818166175189N/A
12/31/2021791205339353N/A
9/30/2021753156101115N/A
6/30/202172513981115N/A
3/31/2021674953942N/A
12/31/2020647-148-197-193N/A
9/30/2020595-190-84-82N/A
6/30/2020634-152-70-69N/A
3/31/2020700-95-131-130N/A
12/31/2019785134N/A151N/A
9/30/2019889213N/A200N/A
6/30/2019935254N/A275N/A
3/31/2019988248N/A413N/A
12/31/20181,005275N/A303N/A
9/30/20181,033106N/A276N/A
6/30/20181,06467N/A210N/A
3/31/20181,08371N/A260N/A
12/31/20171,09358N/A295N/A
9/30/20171,087281N/A360N/A
6/30/20171,08081N/A409N/A
3/31/20171,06565N/A370N/A
12/31/20161,05835N/A407N/A
9/30/20161,047-6N/A326N/A
6/30/20161,028191N/A283N/A
3/31/20161,021201N/A252N/A
12/31/20151,014228N/A320N/A
9/30/20151,037268N/A300N/A
6/30/20151,058314N/A369N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INDV's forecast earnings growth (13.8% per year) is above the savings rate (3.5%).

Earnings vs Market: INDV's earnings (13.8% per year) are forecast to grow slower than the US market (16.4% per year).

High Growth Earnings: INDV's earnings are forecast to grow, but not significantly.

Revenue vs Market: INDV's revenue (2.7% per year) is forecast to grow slower than the US market (11.4% per year).

High Growth Revenue: INDV's revenue (2.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if INDV's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 17:17
End of Day Share Price 2026/05/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Indivior Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Graham Glyn ParryBofA Global Research
Chase KnickerbockerCraig-Hallum Capital Group LLC
Brandon FolkesH.C. Wainwright & Co.